BPC-157vsHMG

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Its mechanism of action is remarkably multifaceted, affecting multiple organ systems and healing pathways simultaneously, which is unusual for a single peptide. The primary mechanism centers on the nitric oxide (NO) system — BPC-157 modulates both constitutive (eNOS) and inducible (iNOS) nitric oxide synthase, and can either promote or inhibit NO production depending on the tissue context and injury state.

BPC-157's regenerative effects are mediated through upregulation of multiple growth factors. It increases expression of vascular endothelial growth factor (VEGF), promoting angiogenesis — the formation of new blood vessels at injury sites, which is critical for delivering oxygen and nutrients for tissue repair. It also upregulates epidermal growth factor (EGF), nerve growth factor (NGF), and hepatocyte growth factor (HGF) receptors, supporting wound healing, nerve regeneration, and organ protection respectively. In tendon and ligament injuries, BPC-157 stimulates fibroblast migration and proliferation, accelerating collagen deposition and organized tissue repair rather than scar formation.

Beyond structural healing, BPC-157 has significant effects on the central and enteric nervous systems. It modulates dopaminergic, serotonergic, GABAergic, and opioid systems, which may explain reported effects on mood, gut function, and pain perception. It protects endothelial function, counteracts the effects of NSAIDs on the gastric mucosa, and has demonstrated cytoprotective effects in models of liver, brain, heart, and intestinal damage. The peptide also interacts with the FAK-paxillin pathway, which is central to cell adhesion and migration during wound healing. Its stability in gastric juice — unusual for a peptide — enables oral administration, making it one of the few peptides effective by both injectable and oral routes.

Human Menopausal Gonadotropin is a purified urinary extract containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, sourced from the urine of postmenopausal women. After menopause, the loss of ovarian negative feedback (estradiol and inhibin) results in dramatically elevated pituitary gonadotropin secretion — FSH and LH levels rise 10-20 fold, providing a natural source of these hormones for pharmaceutical extraction.

The FSH component binds to FSH receptors (FSHR) on Sertoli cells in males and granulosa cells in females. FSHR is a Gs-coupled GPCR that activates cAMP/PKA signaling, driving the expression of genes essential for gametogenesis. In males, FSH-stimulated Sertoli cells produce androgen-binding protein (which concentrates testosterone locally), inhibin B (which provides negative feedback to the pituitary), and multiple growth factors that support spermatogonial proliferation and differentiation through the stages of spermatogenesis. In females, FSH drives follicular development — stimulating granulosa cell proliferation, estradiol synthesis via aromatase induction, and the growth of ovarian follicles from the pre-antral to the pre-ovulatory stage.

The LH component acts on Leydig cells in males (stimulating testosterone production via the LHCGR/cAMP/StAR steroidogenic pathway) and on theca cells in females (stimulating androgen precursor production that granulosa cells convert to estradiol). In females undergoing fertility treatment, the LH component is also critical for final oocyte maturation and ovulation triggering. The combination of both FSH and LH activity in HMG provides more complete gonadal stimulation than either gonadotropin alone — FSH drives the cellular proliferation and maturation processes while LH provides the steroidogenic and final maturation signals. This dual activity is why HMG is sometimes preferred over purified FSH preparations in certain fertility protocols, particularly in hypogonadotropic patients who lack endogenous LH.